Agoracom: Small Cap Investment - Resverlogix Corp. - Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

BearDownAZ

Oct 26, 2020 08:15AM

Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

fuzzyjr

Oct 26, 2020 08:26AM

Apabetalone and Potential COVID-19 Effectiveness

masila

Oct 26, 2020 09:01AM

Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

barsax

Oct 26, 2020 10:32AM

Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

jermainejackson

Oct 26, 2020 11:00AM

Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

KOO-KOO2

Oct 26, 2020 02:04PM

Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

cityslicker99

Oct 26, 2020 03:59PM

Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

barsax

Oct 26, 2020 04:18PM

cityslicker99

Rank: President [?]

Points: 1942 [?]

Votes: 24 Score: 3.8 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

in response to

Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms

barsax

posted on Oct 26, 2020 06:11PM

Many thanks, Barsax. Good job!

Although there are presumably very good theoretical reasons why each of these drugs and ABL could be of benefit in covid-19, the FDA might be worried about possible interactions between them that might have adverse effects. They might require single drug trials to show efficacy before approving a multi-drug cocktail.

4 Recommendations

Re: A Second Publication Shortlists Resverlogix Clinical Candidate Apabetalone for its Potential COVID-19 Effectiveness Including Reducing Cytokine Storms